Business Wire02.19.19
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), has appointed Wayde McMillan as executive vice president and chief financial officer (CFO), effective March 1, succeeding Michael Levitz. To ensure a smooth and successful transition, McMillan has already joined the company and Levitz is continuing with the company in an advisory capacity for a period following the succession effective date.
McMillan is a seasoned executive with more than 20 years of corporate finance and accounting experience. Over the course of his career, he has developed expertise in strategic financial planning and business development at both multi-billion dollar public companies and entrepreneurial startup ventures. Most recently, McMillan served as CFO and vice president of Finance of the Minimally Invasive Therapies Group at Medtronic plc, where he played a key role in integration efforts following the company’s acquisition of Covidien plc in 2015, including reorganizing into the Medtronic Group structure and developing a new global financial plan and strategy.
“We are excited to welcome a leader of Wayde’s caliber to Insulet as the company transitions to profitability, expands internationally, and enters its next phase of rapid growth,” said Shacey Petrovic, president and CEO. “Wayde has significant expertise scaling large organizations and a thorough understanding of the strategies we are pursuing globally to accelerate growth and build on our strong foundation. We look forward to benefitting from Wayde’s experience as we continue to position the company for long-term success and solidify our leadership in the global management of diabetes. On behalf of the Board of Directors and the entire company, I want to thank Mike Levitz for his numerous contributions, as well as his support during this transition period. Over the last four years, Mike has helped develop and execute our strategic imperatives, strengthen our infrastructure and capabilities in support of future growth, and generate exceptional value for shareholders. We wish Mike all the best in his future endeavors.”
Prior to Medtronic’s acquisition of Covidien, McMillan held a variety of leadership positions at Covidien, including CFO and vice president of Finance of the Medical Devices Group & U.S., CFO and vice president of Finance of the Surgical Solutions Business Unit, and vice president of Finance and controller of the Respiratory and Monitoring Solutions Business Unit. McMillan started his career in accounting, audit, financial analysis and investor relations positions at various institutions. He earned a bachelor of science degree in business administration from Merrimack College and an MBA from the Bentley University McCallum Graduate School of Business.
“I am honored to join the team at Insulet, a company with a strong mission dedicated to improving the lives of people impacted by diabetes,” said McMillan. “I look forward to working alongside the Insulet leadership team and contributing to the company’s initiatives to drive growth, profitability and value creation for shareholders.”
Insulet Corporation, headquartered in Massachusetts, is a medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides an alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 150,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives.
On July 1, 2018, Insulet assumed direct operations of its Omnipod Insulin Management System product line in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as Insulet does in the United States and Canada.
McMillan is a seasoned executive with more than 20 years of corporate finance and accounting experience. Over the course of his career, he has developed expertise in strategic financial planning and business development at both multi-billion dollar public companies and entrepreneurial startup ventures. Most recently, McMillan served as CFO and vice president of Finance of the Minimally Invasive Therapies Group at Medtronic plc, where he played a key role in integration efforts following the company’s acquisition of Covidien plc in 2015, including reorganizing into the Medtronic Group structure and developing a new global financial plan and strategy.
“We are excited to welcome a leader of Wayde’s caliber to Insulet as the company transitions to profitability, expands internationally, and enters its next phase of rapid growth,” said Shacey Petrovic, president and CEO. “Wayde has significant expertise scaling large organizations and a thorough understanding of the strategies we are pursuing globally to accelerate growth and build on our strong foundation. We look forward to benefitting from Wayde’s experience as we continue to position the company for long-term success and solidify our leadership in the global management of diabetes. On behalf of the Board of Directors and the entire company, I want to thank Mike Levitz for his numerous contributions, as well as his support during this transition period. Over the last four years, Mike has helped develop and execute our strategic imperatives, strengthen our infrastructure and capabilities in support of future growth, and generate exceptional value for shareholders. We wish Mike all the best in his future endeavors.”
Prior to Medtronic’s acquisition of Covidien, McMillan held a variety of leadership positions at Covidien, including CFO and vice president of Finance of the Medical Devices Group & U.S., CFO and vice president of Finance of the Surgical Solutions Business Unit, and vice president of Finance and controller of the Respiratory and Monitoring Solutions Business Unit. McMillan started his career in accounting, audit, financial analysis and investor relations positions at various institutions. He earned a bachelor of science degree in business administration from Merrimack College and an MBA from the Bentley University McCallum Graduate School of Business.
“I am honored to join the team at Insulet, a company with a strong mission dedicated to improving the lives of people impacted by diabetes,” said McMillan. “I look forward to working alongside the Insulet leadership team and contributing to the company’s initiatives to drive growth, profitability and value creation for shareholders.”
Insulet Corporation, headquartered in Massachusetts, is a medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides an alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 150,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives.
On July 1, 2018, Insulet assumed direct operations of its Omnipod Insulin Management System product line in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as Insulet does in the United States and Canada.
